- Forbes•5 hours ago
Lynn Seely, the CEO of Myovant Sciences, talks to Forbes about the company she just led onto the New York Stock Exchange.
- The Wall Street Journal•3 days ago
After drawing venture investors and collaborator Takeda Pharmaceutical Co. to an early-stage technology for precisely targeted cancer drugs to tumors, Mersana is poised to find out how well this approach ...
- Moody's•8 days agoAstellas Pharma Inc. -- Moody's: Japanese pharmaceutical companies' expiring drugs patents could prompt strategic alliances
Tokyo, October 20, 2016-- Moody's Japan K.K. says that the expiry of key drug patents over the next 1-3 years will pressure the revenues of the rated Japanese pharmaceutical companies, and could prompt ...
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||22.76 - 22.93|
|52wk Range||20.32 - 25.72|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||24.07|
|Avg Vol (3m)||30,295|
|Dividend & Yield||0.87 (3.85%)|